Weekly Recap | Upstream Bio -0.72%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 07:12 AMUPB-8.36%
Weekly Recap | Sellas Life Sciences +15.63%, consensus target well above spotWeekly Review·Oct 24, 2026 at 07:01 AMSLS+1.67%
Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack upWeekly Review·Oct 24, 2026 at 07:00 AMSMMT-0.51%
Weekly Recap | Beigene +2.32%, Tevimbra combination survival data landsWeekly Review·Oct 24, 2026 at 06:49 AMONC-1.21%
Weekly Recap | Moderna -8.22%, sell-off after cancer vaccine dataWeekly Review·Oct 24, 2026 at 06:41 AMMRNA-1.25%MRNY-2.25%
Weekly Recap | Jasper Therapeutics +6.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:41 AMJSPR+2.91%
Weekly Recap | Legend Biotech +4.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:36 AMLEGN+1.96%
Weekly Recap | AEON Biopharma, Inc. +5.84%, spiking then fading after ABP-450 updateWeekly Review·Oct 3, 2026 at 06:14 AMAEON+2.65%
Weekly Recap | AEON Biopharma, Inc. -25.82%, consensus target sits above spotWeekly Review·Sep 19, 2026 at 05:34 AMAEON+2.65%
Weekly Recap | AEON Biopharma, Inc. +35.76%, migraine candidate news drives volume surgeWeekly Review·Sep 12, 2026 at 05:54 AMAEON+2.65%
